Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $5.16M fell 21.4% year over year, ahead of the -26.8% change in trailing-twelve-month research & development. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Research & development amounted to 1237.3% of revenue in FY2025, down 1358.2 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -21.4% holds above the trailing-twelve-month pace of -26.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.16M+5.1% QoQ
Last fiscal yearDec 2025
$20.21M-24.3% YoY
LTMMar 2026
$18.8M-26.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.4%——
1 year-24.3%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
20.21M USD
Year-over-year change
-24.3%
4-year CAGR
-6.5%

Research & Development vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.8% is the 8th highest of 9, against a peer median of +1.9%.
  • Research & development amounts to 593.1% of revenue for RANI, versus a peer median of 928.4%.
RANI Competitors
Research & Development for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M USD+11.4%-23.3%327.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$55.26M USD+60.0%-18.4%314.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding RANI) —+1.9%-6.5%928.4%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.